“We found that a class of agents known as BET bromodomain inhibitors
significantly impeded the growth of triple-negative breast cancer cells
in laboratory as well as animal-model tests,” says the study’s senior
author, Kornelia Polyak, MD, PhD,
of Dana-Farber. “On the basis of these results, such inhibitors will be
tested in patients with triple-negative breast cancer [TNBC] in a phase
2 study and they are also included in ongoing phase 1 trials."...
Click on link below to full story:
Study identifies first potential targeted drug for triple-negative breast cancer and uncovers drug-resistance mechanism - Dana-Farber Cancer Institute | Boston, MA